- Home
- KALV vs SBGI Comparison
KALV vs SBGI Comparison
Compare KALV & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KALV | SBGI |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | 7100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 998.0M |
| IPO Year | 2014 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KALV | SBGI |
|---|---|---|
| Price | $26.80 | $13.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $32.60 | $22.00 |
| AVG Volume (30 Days) | ★ 3.9M | 397.8K |
| Earning Date | 07-09-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.56% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | $50,000,000.00 | ★ $3,169,000,000.00 |
| Revenue This Year | $185.42 | $12.37 |
| Revenue Next Year | $59.23 | N/A |
| P/E Ratio | ★ N/A | $51.04 |
| Revenue Growth | ★ 495.66 | N/A |
| 52 Week Low | $9.83 | $11.89 |
| 52 Week High | $26.85 | $17.88 |
Technical Indicators
Market Signals| Indicator | KALV | SBGI |
|---|---|---|
| Relative Strength Index (RSI) | 74.29 | 42.52 |
| Support Level | $14.22 | $13.02 |
| Resistance Level | $26.85 | $15.49 |
| Average True Range (ATR) | 0.06 | 0.49 |
| MACD | -0.28 | -0.00 |
| Stochastic Oscillator | 76.47 | 31.14 |
Price Performance
Historical ComparisonAbout KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.